TCRT stock has given up its prior gain. Alaunos Therapeutics shares were trading higher after the company filed a patent application for "Identification Of Neoantigen-Reactive T Cell Receptors"

Alaunos Therapeutics Announces $1.12M Direct Offering Of 380,469 Shares And Warrants To Purchase Up To 386,654 Shares At $1.46 Per Share

The offering is expected to close on or about September 21, 2026, subject to the satisfaction of customary closing conditions.The Company intends to use the net proceeds from the offering primarily for general working

Alaunos Therapeutics shares are trading higher after the company filed a patent application for "Identification Of Neoantigen-Reactive T Cell Receptors"

Market-Moving News for September 18th

TCRT: 69% | Alaunos Therapeutics On Thursday Filed Patent Application "Identification Of Neoantigen-Reactive T Cell Receptors" MEDS: 24% | DataMeds AI Settles Litigation Related To Outstanding Debt And